Positives

• In the Phase 2 trial, Long COVID patients showed statistically significant fatigue improvements on PROMIS, FACIT-Fatigue, and physician global assessment scales earlier in the study Oxford Academic.
  
  
• Female patients in particular responded better than male patients to the RNase mechanism, suggesting a defined responder subgroup with persistent viral RNA could benefit PR Newswire.
  
  

Negatives

• Patients did not show a statistically significant difference from placebo on the day-71 primary endpoint, leaving the overall trial result negative Oxford Academic.
  
  
• A patient seeking RSLV-132 will find no commercially available product, with the next development steps and Phase 3 trial timeline unclear clinicaltrials.gov.
  
  

Hurdles & Side Effects

• Patients have to accept six IV infusions over two months to receive a full course, requiring significant clinic time and venous access Oxford Academic.
  
  
• A patient interested in this approach would need to enroll in a future Resolve Therapeutics trial, since the IgG1 fusion biologic is not approved for any indication PR Newswire.